Immunohistochemical expression of GLUT-1 and Ki-67 in chronic plaque psoriasis

American Journal of Dermatopathology

Volumn 35, Issue 7, 2013, Pages 731-737

  Abdou, Asmaa G ^a   Maraee, Alaa H ^a   Eltahmoudy, Mohamed ^a   El Aziz, Reem A ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

GLUT 1; Immunohistochemistry; Ki 67; Proliferation; Psoriasis

Indexed keywords

GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN;

ACANTHOSIS; ADULT; ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FACILITATION; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; SKIN BIOPSY;

ADULT; BIOLOGICAL MARKERS; CELL PROLIFERATION; CHRONIC DISEASE; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; KI-67 ANTIGEN; MALE; PSORIASIS;

EID: 84885018390     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182819da6     Document Type: Article

References (21)

1. Kurd SK, Richardson SK, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol. 2007;3: 171-185.
2. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.
3. Boniface K, Blom B, Liu YJ, et al. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008; 226:132-146.
4. Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet. 2001;10:1793-1805. (Pubitemid 32899097)
5. Chang SL, Hu S, Hung SI, et al. A comparison of Ki-67 antigen presentation in acute generalized exanthematous pustulosis and pustular psoriasis. Arch Dermatol Res. 2010;302:525-529.
6. Adişen E, Gülekon A, Erdem O, et al. The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and Ki-67 expression in psoriasis. J Eur Acad Dermatol Venereol. 2006;20:527-533.
7. Heng MC, Song MK, Harker J, et al. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol. 2000;143:937-949.
8. Gatenby RA, Smallbone K, Maini PK, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007;97:646-653. (Pubitemid 47339892)
9. Weiner MF, Miranda RN, Bardales RH, et al. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. Diagn Cytopathol. 2004;31:294-299. (Pubitemid 39441667)
10. Oliver RJ, Woodwards RT, Sloan P, et al. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer. 2004;40:503-507. (Pubitemid 38220765)
11. Dierckx RA, Van de Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging. 2008;35:1544-1549.
12. Louden BA, Pearce DJ, Lang W, et al. A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10:7.
13. Tao J, Yang J, Wang L, et al. Expression of GLUT-1 in psoriasis and the relationship between GLUT-1 upregulation induced by hypoxia and proliferation of keratinocyte growth. J Dermatol Sci. 2008;51:203-207.
14. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137:559-570. (Pubitemid 32458438)
15. Cabibi D, Aragona F, Guarnotta C, et al. Glut-1 expression and in situ CD1a/CD57 immunologic deficit in keratoacanthoma and squamous cell carcinoma of immunocompetent patients. Appl Immunohistochem Mol Morphol. 2011;19:239-245.
16. Carvalho KC, Cunha IW, Rocha RM, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics. 2011; 66:965-972.
17. Selcuk FK, Polt A, Klin ÇF, et al. p53, Fas (APO 1) and Ki 67 immunostaining in testicular germ cell tumors and correlation with pathologic stage, tumor size, necrosis and vascular invasion. Turk J Cancer. 2003; 33:137-143.
18. Jiamton S, Suthipinittharm P, Kulthanan K, et al. Clinical characteristics of Thai patients with psoriasis. J Med Assoc Thai. 2012;95:795-801.
19. Leong TT, Fearon U, Veale DJ. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep. 2005;7: 325-329.
20. Amin MM, Azim ZA. Immunohistochemical study of osteopontin, Ki-67, and CD34 of psoriasis in Mansoura, Egypt. Indian J Pathol Microbiol. 2012;55:56-60.
21. Creamer D, Allen MH, Sousa A, et al. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol. 1997;136:859-865. (Pubitemid 27283516)